Boosting NAD: An opportunity for metabolic reprogramming of Th17 cells in psoriatic disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37729874.
- Also identified by DOI 10.1016/j.xcrm.2023.101163 and PMC identifier 10518578.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metabolic reprogramming of CD4 T cells has become an opportunity for adjunctive therapies. Here, Han et al. show that boosting NAD<sup>+</sup> blunts systemic Th17 responses and increases antioxidant pathways through arginine and fumarate-mediated activation of NRF2 transcription factor.
Medical subject headings
- NAD
- Th17 Cells